Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ANAdlai Nortye Ltd. logo

Adlai Nortye Ltd. (ANL)

NASDAQ Global Market · Currency in USD
$10.58 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.
$10.58 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$10.58
Open
$10.63
Day's Range
$10.36 – $10.63
52 Week Range
$0.88 – $17.25
Volume
79,538
Avg. Volume
218,918
Market Cap
$561.59M
Beta (5Y Monthly)
1.16
PE Ratio (TTM)
--
EPS (TTM)
-$1.41
Earnings Date
Mar 3, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$37.33

Profile: Adlai Nortye Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
109
CEO
Yang Lu

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas.

Earnings

Next report: Wed, Mar 3, 2027
EPS estimate -$0.15 · Revenue est. $3.47M
DateEst.Actual
Aug 14, 2026-$0.06-$0.04Beat
Apr 10, 2026-$0.18-$0.81Miss
Dec 29, 2025-$0.18-$0.18Beat
Aug 7, 2025-$0.18-$0.18Beat
Apr 30, 2025-$0.53-$0.22Beat
Feb 26, 2025-$0.53-$0.22Beat

Analyst view

Consensus price target
$37.33 ▲ +252.8%
Range $31.00 – $49.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ANL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.